BEAM

SEC source: 0000950170-24-041432 · ownership.xml · derivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,336

Underlying: Common Stock · 99,336 shares

Expires 2028-05-08

F3 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase 99,336 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0000950170-24-041426 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,979

Underlying: Common Stock · 12,979 shares

Expires 2029-02-13

F4 · derivative.exercise_date: On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares.

SEC source: 0000950170-24-041426 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,318

Underlying: Common Stock · 27,318 shares

Expires 2028-05-08

F3 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares.

SEC source: 0000950170-24-041441 · ownership.xml · nonDerivative · entry 2

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,060

F3 · kind: The shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.24 to $31.00, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-041441 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,590

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.17, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-041438 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,594

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-041437 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,137

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-041432 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,058,343

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-041426 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,616

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-039319 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,076,445

F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

F4 · balance_after: Includes 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2024.

SEC source: 0000950170-24-040154 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,583

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

F2 · balance_after: Includes 283 shares and 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively.

SEC source: 0000950170-24-040152 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,747

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

F2 · balance_after: Includes 363 shares and 415 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively.

SEC source: 0000950170-24-040151 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,150

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-040150 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,995

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-039319 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 998,262

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.374 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 1,235,511

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $31.25 to $31.58. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 1,281,188

F1 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $30.25 to $31.25. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,771,913

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,773,068

SEC source: 0000950170-24-010480 · ownership.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-24-010479 · ownership.xml · derivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date

SEC source: 0000950170-24-010478 · ownership.xml · derivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-24-010477 · ownership.xml · derivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2034-01-31

F4 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-010477 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,058,262

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023.

SEC source: 0000950170-24-010474 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-24-002480 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,495

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0001209191-23-059756 · doc4.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,773,478

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-23-070395 · ownership.xml · derivative · entry 1

Shaw Christi · CIK 0001702473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,046

Underlying: Common Stock · 39,046 shares

Expires 2033-12-13

F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date.

SEC source: 0000950170-23-065868 · ownership.xml · derivative · entry 6

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,918

Underlying: Common Stock · 5,818 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-23-065868 · ownership.xml · derivative · entry 5

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,492

Underlying: Common Stock · 4,182 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-23-065868 · ownership.xml · nonDerivative · entry 4

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,402

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

SEC source: 0000950170-23-065868 · ownership.xml · nonDerivative · entry 3

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,402

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

SEC source: 0000950170-23-065868 · ownership.xml · nonDerivative · entry 2

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

SEC source: 0000950170-23-065868 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

SEC source: 0000950170-23-057499 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,469

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0000950170-23-054850 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,005

Underlying: Common Stock · 90,900 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0000950170-23-054850 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-23-051915 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,402

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 8

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,002

Underlying: Common Stock · 1,206 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,250

F2 · kind: These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,457

Underlying: Common Stock · 21,846 shares

Expires 2029-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,208

Underlying: Common Stock · 69,438 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,250

F2 · kind: These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 181,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

SEC source: 0000950170-23-040574 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,917

F1 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

SEC source: 0000950170-23-027037 · ownership.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-23-027060 · ownership.xml · derivative · entry 4

Burow Kristina · CIK 0001569248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2033-06-06

F4 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-23-027049 · ownership.xml · derivative · entry 1

COOPER GRAHAM K · CIK 0001396943 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.